Afatinib: Added benefit in certain mutations confirmed

In advanced non-small cell lung cancer, the new tyrosine-kinase inhibitor is more effective than combination chemotherapy in patients with certain mutations, reviewers report.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1TWjrYR